Brief: Lee's Pharmaceutical Holdings Says Treprostinil Obtained Approval For Manufacturing And Marketing From Nmpa
19/03/2020 13:36
March 19 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* TREPROSTINIL OBTAINED APPROVAL FOR MANUFACTURING AND
MARKETING
FROM NMPA
Source text for Eikon: urn:newsml:reuters.com:*:nHKSxvlk7
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA